Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,047 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tumor, Breast Clear all
Terminated Phase 1 Interventional

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

NCT02598427
View directory record Official record
Conditions
HER2 Positive Untreated Metastatic Breast Cancer, Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Interventions
Pertuzumab, Trastuzumab
Drug
Lead sponsor
Kimberly Blackwell
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 19, 2026, 8:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors

NCT04042870
View directory record Official record
Conditions
Breast Cancer
Interventions
Joint Loosening Yoga
Behavioral
Lead sponsor
AshtaYoga, LLC
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 19, 2026, 8:01 AM EDT
Completed Not applicable Interventional

MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors

NCT07782866
View directory record Official record
Conditions
Breast Cancer
Interventions
Transcutaneous vagus nerve and acupuncture point stimulation
Device
Lead sponsor
The Healing Consciousness Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Meadowbrook, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 19, 2026, 8:01 AM EDT
Completed Phase 1 Interventional

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

NCT00849329
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, lapatinib plus esomeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 19, 2026, 8:01 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population

NCT01569802
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Rose Imaging Specialists, P.A.
Other
Eligibility
30 Years and older · Female only
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Sep 19, 2026, 8:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

NCT07749586
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ARV-6723, Pembrolizumab, SOC
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 19, 2026, 8:01 AM EDT
Active, not recruiting Phase 2 Interventional

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

NCT03546686
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery, Ipilimumab, Nivolumab
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Columbus, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 19, 2026, 8:01 AM EDT
Completed Phase 2 Interventional

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

NCT00148070
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Docetaxel, Erythromycin Breath Test (ERMBT)
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 19, 2026, 8:01 AM EDT
Recruiting Phase 2 Interventional

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy

NCT06185205
View directory record Official record
Conditions
Breast Cancer
Interventions
Accelerated partial breast irradiation
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
45 Years to 79 Years · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 19, 2026, 8:01 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer

NCT03454529
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Simvastatin
Other · Drug
Lead sponsor
Michael Simon
Other
Eligibility
19 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 19, 2026, 8:01 AM EDT
Recruiting Phase 1 Interventional

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029
View directory record Official record
Conditions
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Interventions
ONM-501, Cemiplimab
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 19, 2026, 8:01 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

NCT02124902
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Docetaxel, Carboplatin, FDG-PET/MR
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 19, 2026, 8:01 AM EDT
Recruiting No phase listed Observational

De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You

NCT05134779
View directory record Official record
Conditions
Breast Cancer
Interventions
Live Biobank
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 19, 2026, 8:01 AM EDT
Terminated Phase 1 Interventional

A Safety Study of SGN-CD47M in Patients With Solid Tumors

NCT03957096
View directory record Official record
Conditions
Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma, Breast Carcinoma, Ovarian Carcinoma, Exocrine Pancreatic Carcinoma, Gastric Carcinoma, Melanoma
Interventions
SGN-CD47M
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 19, 2026, 8:01 AM EDT
Recruiting Phase 1 Interventional

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions
Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 19, 2026, 8:01 AM EDT
Completed Phase 2 Interventional Results available

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

NCT01149083
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Veliparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 19, 2026, 8:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Fujifilm Feature Comparison Reader Study to Compare Old vs New Processing

NCT03586583
View directory record Official record
Conditions
Breast Cancer
Interventions
FBP, ISR
Device
Lead sponsor
Fujifilm Medical Systems USA, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 19, 2026, 8:01 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 19, 2026, 8:01 AM EDT
Completed Phase 1Phase 2 Interventional

Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant

NCT00977275
View directory record Official record
Conditions
Breast Cancer
Interventions
Interstitial Implant Brachytherapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 19, 2026, 8:01 AM EDT
Terminated Phase 1Phase 2 Interventional

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

NCT00003086
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CAF regimen, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, fluorouracil, ifosfamide, melphalan, paclitaxel, thiotepa, peripheral blood stem cell transplantation, samarium Sm 153 lexidronam pentasodium
Biological · Drug · Procedure + 1 more
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 19, 2026, 8:01 AM EDT
Active, not recruiting Not applicable Interventional

Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction

NCT05223322
View directory record Official record
Conditions
Breast Cancer
Interventions
Taking Charge during Treatment (TCT) Intervention
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 19, 2026, 8:01 AM EDT
Terminated Not applicable Interventional

WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial Participation for Rural and Low Income Women

NCT07644702
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Educational Intervention, Patient Navigation, Supportive Care
Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 74 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 19, 2026, 8:01 AM EDT
Active, not recruiting No phase listed Observational

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

NCT01517945
View directory record Official record
Conditions
Breast Cancer, Rare Cancer
Interventions
AIM materials and assessments
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 19, 2026, 8:01 AM EDT
Not yet recruiting Phase 3 Interventional

Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

NCT07723469
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
BCS + SRG-514, BCS
Drug · Procedure
Lead sponsor
SURGE Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 19, 2026, 8:01 AM EDT